Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | ABL2 | P42684 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ULK1 | O75385 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6618798 | 0.87 | ADH1A (0.46) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL6618596 | 0.87 | ADH1A (0.46) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL7945647 | 0.79 | ADH1A (0.45) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL19057483 | 0.77 | P4HB (0.51) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL30852737 | 0.77 | P4HB (0.51) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL18822196 | 0.77 | P4HB (0.51) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL30360049 | 0.77 | P4HB (0.51) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL7952123 | 0.77 | HRH4 (0.44) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL7959056 | 0.77 | KMT2A (0.45) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL7945652 | 0.77 | KDM4E (0.43) | ADH1AKITFLT1FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369705-A1 | COMBINATION THERAPY UTILIZING DNA ALKYLATING AGENTS AND ATR INHIBITORS | MERCK PATENT GMBH (DE) | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369705-A1 | COMBINATION THERAPY UTILIZING DNA ALKYLATING AGENTS AND ATR INHIBITORS | ATR, TOP2A, TOP1 | ADH1A 3241/4885KIT 2021/4885FLT1 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.